Canaccord raised the firm’s price target on Regeneron to $1066 from $992 and keeps a Buy rating on the shares. The firm said US Eylea revenues in 3Q23 were below consensus ($1.49B vs $1.53B) while high dose Eylea revenues beat consensus ($59M vs $29M). Importantly, Dupixent surprised with an FDA nod to possible sBLA submission in COPD earlier than expected based on an interim analysis in 4Q23.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
- Regeneron price target raised to $935 from $925 at Barclays
- Regeneron upgraded to Outperform from Market Perform at Raymond James
- Regeneron Reports Third Quarter 2023 Financial and Operating Results
- Regeneron reports Q3 adjusted EPS $11.59, consensus $10.77